StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$69.00−0.84 (-1.20%)

Close on Nov 13, 2026Market cap $16.84BP/E 20.7Yield –

Exelixis EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Exelixis's EV/EBITDA was 16.8× on Nov 11, 2026, against 13.1× a year earlier. Over the last 5 years it ranged from 9.5× to 96.1×, with a median of 15.7×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202616.8×+3.8
2025Dec 31, 202513.0×−2.1
2024Dec 31, 202415.1×−81.0
2023Dec 29, 202396.1×+86.6
2022Dec 30, 20229.5×−11.4
2021Dec 31, 202120.9×−8.3
2020Dec 31, 202029.2×+18.0
2019Dec 31, 201911.1×−3.1
2018Dec 31, 201814.3×−36.9
2017Dec 29, 201751.2×+44.1
2012Oct 31, 20127.1×–

More Exelixis figures

See a number that looks wrong?